Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | DRD1 | P21728 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | HTR1B | P28222 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.67 |
| ▸ | HTR6 | P50406 | 19/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774519 | 1.00 | CHRM2 (0.67) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL1697447 | 0.92 | CHRM2 (0.64) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL1067208 | 0.86 | CHRM2 (0.64) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL1067210 | 0.86 | CHRM2 (0.64) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL19171434 | 0.83 | HTR6 (0.54) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL29387278 | 0.81 | CHRM2 (0.57) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| SCHEMBL19171029 | 0.80 | HTR1B (0.80) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Eletriptan SCHEMBL798473 | 0.80 | HTR1B (1.00) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Eletriptan SCHEMBL1556539 | 0.80 | HTR1B (1.00) | CHRM2HTR1AADRA2ACHRM1DRD1 | |
| Eletriptan SCHEMBL29414096 | 0.80 | HTR1B (1.00) | CHRM2HTR1AADRA2ACHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071669-A1 | PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF | USV Limited B.S.D. Mar (IN) | 2012-03-22 | — | — | US | disclosed |
| US-20120071669-A1 | PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF | USV Limited B.S.D. Mar (IN) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071669-A1 | PROCESS FOR PREPARATION OF ELETRIPTAN AND SALT THEREOF | HTR3C, SLC6A4, HTR3A | CHRM2 1355/4885HTR1A 12/4885ADRA2A 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.